Reference
- Young EI. MDA Clinical and Scientific Conference 2022, Nashville TN, 13–16 March 2022. https://mdaconference.org/node/1519
Reference
- Gibbons C, Pagnini F, Friede T, Young CA. Treatment of fatigue in amyotrophic lateral sclerosis/motor neurone disease. Cochrane Database Syst Rev. 2018;1:CD011005.
References
- Ward AL, Hammond S, Holsten S, Bravver E, Brooks BR. Power wheelchair use in persons with amyotrophic lateral sclerosis: changes over time. Assist Technol. 2015;27:238–45.
- Ward AL, Sanjak M, Duffy K, et al. Power wheelchair prescription, utilization, satisfaction, and cost for patients with amyotrophic lateral sclerosis: preliminary data for evidence-based guidelines. Arch Phys Med Rehabil. 2010;91:268–72.
References
- Nakajima T, Sankai Y, Takata S, et al. Cybernic treatment with wearable cyborg Hybrid Assistive Limb (HAL) improves ambulatory function in patients with slowly progressive rare neuromuscular diseases: a multicentre, randomised, controlled crossover trial for efficacy and safety (NCY-3001). Orphanet J Rare Dis. 2021;16:304.
- Miura K, Tsuda E, Kogawa M, et al. Effects of gait training with a voluntary-driven wearable cyborg, Hybrid Assistive Limb (HAL), on quality of life in patients with neuromuscular disease, able to walk independently with aids. J Clin Neurosci. 2021;89:211–5.
Reference
- García Martín G, Perez Errazquin FC, Muñoz M, et al. Esclerosis lateral amiotrófica y anticuerpos anti-CV2. ¿Asociación paraneoplásica? [Amyotrophic lateral sclerosis and anti-CV2 antibodies. Paraneoplastic association?]. Neurologia. 2007;22:406–9.
References
- International Patient Decision Aid Standards (IPDAS). Available at: www.ipdas.ohri.ca.
- Ottawa patient decision aids evaluation measures. Available at: https://decisionaid.ohri.ca/eval.html.
References
- Obrador E, Salvador R, López-Blanch R, et al. Oxidative stress, neuroinflammation and mitochondria in the pathophysiology of amyotrophic lateral sclerosis. Antioxidants. 2020;9:901.
- Martínez Leo EE, Peñafiel AM, Hernández Escalante VM, Cabrera Araujo ZM. Ultra-processed diet, systemic oxidative stress, and breach of immunologic tolerance. Nutrition. 2021;91–92:111419.
- Simões B. d S, Barreto SM, Molina M. d C B, et al. Consumption of ultra-processed foods and socioeconomic position: a cross-sectional analysis of the brazilian longitudinal study of adult health. Cad Saúde Pública. 2018;34:
Reference
- Zicchieri AD, Conte SF, De Rossi N. CMS-27: Using a design-build approach to improve international ALS research news access in Italy. Poster presented at the Motor Neurone Disease Association Virtual 31st International Symposium on ALS/MND, 9–11 December 2020; 2020.
References
- D’Alvano G, Buonanno D, Passaniti C, et al. Support needs and interventions for family caregivers of patients with amyotrophic lateral sclerosis (ALS): a narrative review with report of telemedicine experiences at the time of COVID-19 pandemic. Brain Sciences. 2021;12:49.
- Dogba MJ, Dossa AR, Breton E, Gandonou-Migan R. Using information and communication technologies to involve patients and the public in health education in rural and remote areas: a scoping review. BMC Health Serv Res. 2019;19:128.
References
- van Eijk RPA, Bakers JNE, van Es MA, et.al. Implications of spirometric reference values for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:473–80.
- Young EI. MDA Clinical and Scientific Conference 2022, Nashville TN, 13–16 March 2022. https://mdaconference.org/node/1519.
References
- CADTH. 2020. CADTH Reimbursement Reviews. Available at: https://www.cadth.ca/cadth-reimbursement-reviews.
- Garces K, Husereau D, Skidmore B, et al. 2003. Technology report no. 37.
- CADTH Canadian Drug Expert Committee Recommendation. 2019. CADTH common drug reviews.
Reference
- Ishikawa T, Narita Y, Imura T, Tanaka Y, Nakai M, Fukuroku K, et al. A half-day education program for healthcare students on communication support for people with amyotrophic lateral sclerosis. J Commun Healthcare. 2021;14:114–25.
Reference
- Wong JY, De Vivo I, Lin X, Fang SC, Christiani DC. The relationship between inflammatory biomarkers and telomere length in an occupational prospective cohort study. PLOS One. 2014;9:e87348.
References
- Bensimon G, Lacomblez L, Meininger V, ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994; 330:585–91.
- Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347:1425–31.
- Fang T, Al Khleifat A, Meurgey JH, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17:416–22.
References
- Watanabe S, Kimura T, Suenaga K, et al. Decreased chloride levels of cerebrospinal fluid in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2009;285:146–8.
- Qureshi M, Shui A, Dibernardo AB, et al. Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008;9:369–74.
- Hadjikoutis S, Wiles CM. Venous serum chloride and bicarbonate measurements in the evaluation of respiratory function in motor neuron disease. QJM. 2001;94:491–5.
- Melo J, Homma A, Iturriaga E, et al. Pulmonary evaluation and prevalence of non-invasive ventilation in patients with amyotrophic lateral sclerosis: a multicenter survey and proposal of a pulmonary protocol. J Neurol Sci. 1999;169:114–7.
- Stambler N, Charatan M, Cedarbaum JM. ALS CNTF Treatment Study Group. Neurology. 1998;50:66–72.